Information Provided By: 
Fly News Breaks for February 14, 2017
ZLTQ, AGN
Feb 14, 2017 | 07:45 EDT
RBC Capital analyst Randall Stanicky says that Allergan's (AGN) acquisition of ZELTIQ (ZLTQ) is "expensive," but creates significant opportunities for Allergan, including "broad coverage" of the "heavily under-penetrated" aesthetics market and the ability to cross-sell to its current aesthetics customers. The analyst keeps a $279 price target and an Outperform rating on Allergan.
News For AGN;ZLTQ From the Last 2 Days
There are no results for your query AGN;ZLTQ
